Benefits of SGLT-2 inhibitors: Beyond glycemic control

Zoltán, B. ✉; Lívia, S.

Magyar nyelvű Tudományos Szakcikk (Folyóiratcikk)
Megjelent: LEGE ARTIS MEDICINAE 0866-4811 2063-4161 31 (3-4) pp. 89-97 2021
  • SJR Scopus - Medicine (miscellaneous): Q4
Azonosítók
In the recent years, according to international and Hungarian guidelines, in addition to lifestyle modification, metformin is the preferred initial glucose-lowering drug for most people with type 2 diabetes, if not contraindicated. Sodium glucose co-transporter-2 inhibitors have been shown to reduce progression of chronic kidney disease, or kidney failure, as well as the risk of hospitalizations for congestive heart failure and (mainly in secondary prevention) cardiovascular death in patients with type 2 diabetes. For major adverse cardiovascular events and for the renoprotection, there seems to be no class effect. On the other hand, a class effect of sodium glucose co-transporter-2 inhibitors is evident for hospitalization for heart failure. In this review the authors summarize novel data about sodium glucose cotransporter-2 inhibitors, and about their new perspectives in the near future. © 2021 Literatura Medica Publishing House. All rights reserved.
Hivatkozás stílusok: IEEEACMAPAChicagoHarvardCSLMásolásNyomtatás
2021-12-05 20:56